Savara Inc (SVRA) - Cash Flow Conversion Efficiency

Latest as of December 2025: -0.123x

Based on the latest financial reports, Savara Inc (SVRA) has a cash flow conversion efficiency ratio of -0.123x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-25.06 Million) by net assets ($203.13 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Savara Inc (SVRA) net asset quality to measure how much of total assets are equity-financed.

Savara Inc - Cash Flow Conversion Efficiency Trend (2000–2025)

This chart illustrates how Savara Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check how high is Savara Inc's earnings quality to evaluate the quality of earnings relative to operating cash generation.

Savara Inc Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Savara Inc ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Electro Optic Systems Holdings Ltd
AU:EOS
-0.063x
FAWER Automotive Parts Ltd Co
SHE:000030
0.027x
Wuxi Xinhongye Wire & Cable Co. Ltd. A
SHE:301310
N/A
Dorian LPG Ltd
NYSE:LPG
0.044x
Hyundai Wia
KO:011210
0.053x
Safety Insurance Group Inc
NASDAQ:SAFT
-0.020x
McEwen Mining Inc.
TO:MUX
0.019x
Wuxi Online Offline Communication Information Technology Co. Ltd.
SHE:300959
N/A

Annual Cash Flow Conversion Efficiency for Savara Inc (2000–2025)

The table below shows the annual cash flow conversion efficiency of Savara Inc from 2000 to 2025. For the full company profile with market capitalisation and key ratios, see Savara Inc (SVRA) market capitalisation.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-12-31 $203.13 Million $-101.04 Million -0.497x +4.28%
2024-12-31 $171.45 Million $-89.09 Million -0.520x -42.85%
2023-12-31 $140.37 Million $-51.06 Million -0.364x -13.46%
2022-12-31 $107.78 Million $-34.55 Million -0.321x -15.58%
2021-12-31 $144.50 Million $-40.08 Million -0.277x +55.17%
2020-12-31 $64.38 Million $-39.84 Million -0.619x -39.45%
2019-12-31 $101.70 Million $-45.12 Million -0.444x --
2018-12-31 $0.00 $-39.27 Million x --
2017-12-31 $119.31 Million $-28.23 Million -0.237x -201.43%
2016-12-31 $-35.88 Million $-8.37 Million 0.233x +116.92%
2015-12-31 $23.89 Million $-32.95 Million -1.379x -228.28%
2014-12-31 $58.66 Million $-24.64 Million -0.420x -12.91%
2013-12-31 $47.81 Million $-17.79 Million -0.372x -11.72%
2012-12-31 $41.79 Million $-13.92 Million -0.333x -40.42%
2011-12-31 $56.78 Million $-13.47 Million -0.237x +24.12%
2010-12-31 $26.69 Million $-8.34 Million -0.313x +83.47%
2009-12-31 $6.67 Million $-12.62 Million -1.891x +52.35%
2008-12-31 $6.00 Million $-23.79 Million -3.968x -526.87%
2007-12-31 $31.03 Million $-19.64 Million -0.633x +19.92%
2006-12-31 $19.96 Million $-15.77 Million -0.790x -153.12%
2005-12-31 $-7.83 Million $-11.65 Million 1.488x +456.18%
2004-12-31 $12.39 Million $-5.18 Million -0.418x +23.41%
2003-12-31 $4.12 Million $-2.25 Million -0.545x -142.20%
2002-12-31 $-852.73K $-1.10 Million 1.292x -51.78%
2001-12-31 $-638.49K $-1.71 Million 2.680x +1922.59%
2000-12-31 $14.61 Million $-2.15 Million -0.147x --

About Savara Inc

NASDAQ:SVRA USA Biotechnology
Market Cap
$1.12 Billion
Market Cap Rank
#8557 Global
#2462 in USA
Share Price
$5.46
Change (1 day)
-1.44%
52-Week Range
$2.57 - $6.94
All Time High
$45.57
About

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. was founded in 2007 and is headquartered in Langhorne,… Read more